2016
2 3 5 6 7 25 33 50 65 74 74 75 76 78 79 81 190
IMS Health Inc.IMS45.6% IMS 62.7% IMS 43.9% 241510 mab AMD II 18 pegsiticase 3,400 7,800 2
David Ross PARKINSON Cricket Square, Hutchins Drive PO Box 2681 Grand Cayman, KY1-1111 Cayman Islands 1 36 1 3 Conyers Trust Company (Cayman) Limited Cricket Square, Hutchins Drive PO Box 2681 Grand Cayman, KY1-1111 Cayman Islands 183 17 1712 1716 3
36 1 22 181 27 1530 www.3sbio.com 10 14 77 334 Conyers Dill & Pearman Cricket Square Hutchins Drive PO Box 2681 Grand Cayman KY1-1111 Cayman Islands 4
656,145 875,396 1,130,854 1,673,126 2,797,289 585,641 792,217 1,043,373 1,431,215 2,395,021 EBITDA 135,721 231,663 399,528 660,705 1,141,324 EBITDA 164,445 410,457 518,791 734,136 1,148,730 101,877 96,056 291,728 526,230 714,254 131,611 274,853 410,991 599,661 721,660 101,666 95,892 291,728 526,280 712,564 1,476,301 1,268,326 2,306,441 6,630,432 11,038,802 97,062 186,523 1,362,849 994,967 4,272,460 1,379,239 1,081,803 943,592 5,635,465 6,766,342 5
GLP-1Byetta GLP-1 Bydureon Byetta 150 20172017 18 10 GMP SSS07 6
(rhtpo)ims 45.6% IMS(TNF) 62.7% IMS (rhepo)43.9% (1) 38.5%41.69% (2) 0.73% 1,033.3 7
(1)43.42% 2,713.8125,765,500 (2) 12.04% 1,218.0 97.78% 8
MSCI Inc. MSCI 2015 100 100 85 AstraZeneca PLC AstraZeneca AstraZeneca 50,000,00050,000,000AstraZeneca AstraZeneca Byetta Bydureon single dose tray Bydureon dual chamber pen Bydureon auto-injectorbyetta Bydureon PEGTAS102 EGFR PegsiticasePegsiticaseSorrento Therapeutics, Inc.SRNE SorrentoTCAR-T rhepo 9
PIC/S Beyetta BydureonAstraZeneca GMP CIT ITPCIT ITP 214 CIT ITP CIT ITP CIT ITP 10%10% CITPIC/SPIC/S GMP PIC/S PIC/SPIC/S PIC/S Etanercept Etanercept IMS62.7% 846 18 10
rhepo CKD CIA rhepo 36,000 IU rhepo 10,000 IU rhepo (1) CKD(2) CIA rhepo rhepo rhepo rhepo IMS rhepo15.9%rhepo13.5% 1004II 11
241510 AMDII Sorrento CAR-T SSS06 SSS21 SSS17 302 NDA 304 NDA 602 SSS23 701 601t SSS19 SSS25 SSS24 CRC SSS22 301 SSS07 601a AMD SSS11 ITP 608 SSS20 ITP AP506 Bydureon single dose tray II IDA Bydureon dual chamber pen II IDA KW303 12
1,9292301,130 2,0005,900 AstraZeneca500Beyetta 150 NuPIAOSSS07Apexigen Inc. Pegsiticase 602EGFR NuPIAO NuPIAO 13
SSS07 EGFR EGFRCRC Pegsiticase Selecta Biosciences, Inc. Pegsiticase PEG Topo-I Topo-I PEGPEG CRC ITP (eltrombopag tablets) rhtpo IMSITP14.8 20.5% TAS102TAS102 TAS102 CRC CRC 14
VEGFHer2Her2 HIF-PHVEGFR2 38,000 AstraZeneca 15
2,797.3 1,673.11,124.267.2%(1) (2) 765.0 605.1159.926.4% 27.2% 786.2 925.2 842.382.99.8% 28.0% 772.8 727.245.66.3% rhepo 95.6 43.5 52.1 120.0%677.2 683.7 6.51.0% 27.5% 16
50.0 32.317.855.1% 223.2 103.3 Sirton Pharmaceuticals S.p.ASirton 241.9 402.314.4% (1) (2) (3) 2,395.0 1,431.2963.867.3% 215.6 208.6 17
7.03.3%(1)(2) (3) 1,017.2 585.6431.673.7%(1)(2) (3) 35.0%36.4% 301.2 301.0 0.20.1% (1) AstraZeneca85.7 107.1(2) (i) 22.6(ii) 46.6 220.8 7.9%7.5% 18
282.2 142.7139.697.8% 124.7 147.7 26.5121.2456.5% 135.8 61.674.2120.4% 58.516.0% 10.5% EBITDA EBITDAEBITDA(a) AstraZeneca(b) (c)(d) 28.8% (e) EBITDA414.656.5% 1,148.7 EBITDA480.6 72.7%1,141.3 19
(a) AstraZeneca(b) (c)(d)28.8% (e) 721.7 599.7 122.020.3% 714.3 526.2188.035.7% 209.2 3,565.3 75.0 20
1,004.3 687.0 1,097.1 1,990.4 3.6 2.0 3,059.1 405.0 3,985.1 1,467.6 5.9 30.3 7.2% 45.2% 21
8.2 6.8180.3 27.4 (1)Sirton(2) 50.01.8%Sirton (1) 52.3362.9 (2) 43.138.6 200250 3,4652,177 498.0 317.4 22
23
24
54 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 25
13) 14) 15) Fordham University 44 1) 2) 3) 4) 5) 26
6) 7) Grand Path Holdings Limited 8) 9) 10) Globe Metals & Mining Limited GBE TPI 46 (i) (ii) (iii) 27
56 (i) (ii) (iii) (iv) 44 002570Biosensors International Group, Ltd.B20 2186 28
42 PAG Asia Capital 48 Zhaopin Limited ZPIN JMU LimitedJMUAutohome Inc. ATHM Renren Inc. RENN David Ross PARKINSON 67 Parkinson ESSA Pharma Inc.EPIX Tocagen Inc.Cerulean Pharma, Inc. CERU Threshold Pharmaceuticals, Inc. THLDNew Enterprise Associates ParkinsonNodality, Inc. Biogen IdecAmgen Inc.AMGN Novartis Parkinson Gleevec Femara Zometa Vectibix(AACR) Parkinson 12 Andrew H. WeinbergParkinson 29
54 Cornell Law School 52 Kadmon CorporationKadmon China Kadmon Novartis NovartisImClone Systems12 cetuximab Erbitux ramucirumab Cyramza necitumumab (Portrazza ) olaratumab (Latruvo )ramucirumab necitumumabcetuximab olaratumab Dalhousie Genentech 19050 48 30
51 47 Fresenius-Kabi China Fresenius-Kabi China General Electric Renewable Energy ITT Canon (Xiamen) Electronics Co., Ltd 60 35 Sirton 38 Perlos (Beijing) Electronic and Telecommunication Component Co., Ltd. 31
56 000963 00512Schering-Plough Pharmaceutical Research Institute Merck 52 32
1 74 7 24 47 48 5 33
24.1%29.0% 9.6%10.3% 20.0%45.6% 6.2%17.9% 5% 14 33 34
1,128.820331.00 1.000.00001 100,000 112,882,0330.00001 50% 10% 50% 50%56,441,017 17,000,000 9.10 125,765,500 78 4,833.8 4,502.9 35
31 David Ross PARKINSON 84(1) 36
2532 3.133.13 37
42 8 9 10 32 38
13.51(2) (a) (e) (g) XVXV78 352 10 (1) (2) 599,367,030 (L) 23.67% (3) 116,849,920 (L) 4.61% (4) 25,465,630 (L) 20,000,000 (L) 45,445,630 (L) 1.01% 0.79% 1.79% (5) 32,197,350 (L) 1.27% (L) (L) 1. 2,532,313,570 2. 599,367,030 3. Triple Talent Enterprises LimitedTTE TTE 116,849,920 39
4. Joint Palace Group LimitedJPG JPG 25,465,630 The Empire TrustThe Empire Trust20,000,000 The Empire Trust 5. Known Virtue International LimitedKVI KVI 32,197,350 XVXV7 8 352 40
336 XV23 (1) Decade Sunshine LimitedDSL 599,367,030 (L) 23.67% Century Sunshine LimitedCSL (2) 599,367,030 (L) 23.67% (2) 599,367,030 (L) 23.67% Lambda International Limited (2) 599,367,030 (L) 23.67% (3) 599,367,030 (L) 6,200,010 (L) 23.67% 0.24% 605,567,040 (L) 23.91% TMF (Cayman) Ltd. (4) 675,856,160 (L) 26.69% CS Sunshine Investment Limited (5) 712,258,360 (L) 28.13% CPEChina Fund, L.P. (5) 712,258,360 (L) 28.13% CITIC PE Associates, L.P. (5) 712,258,360 (L) 28.13% CITIC PE Funds Limited (5) 712,258,360 (L) 28.13% CITICPE Holdings Limited (5) 712,258,360 (L) 28.13% (5) 712,258,360 (L) 28.13% (5) 712,258,360 (L) 28.13% (5) 712,258,360 (L) 28.13% BlackRock, Inc. (6) 143,210,284 (L) 5.66% 1,407,000 (S) 0.06% (L) (S) 1. 2,532,313,570 2. DSL CSL CSLDSL 599,367,030Lambda International LimitedCSL 42.60% 35.65%599,367,030 3. 599,367,030 Hero Grand Management Limited100% Hero Grand Management Limited 6,200,010 4. TMF (Cayman) Ltd. 599,367,03056,489,13020,000,000 TMF (Cayman) Ltd. 5. CS Sunshine Investment Limited CPEChina Fund, L.P.CPEChina Fund, L.P.CITIC PE Associates, L.P. CITIC PE Associates, L.P. CITIC PE Funds Limited CITICPE Holdings Limited CITIC PE Funds Limited100%CITICPE Holdings Limited 35% CITICPE Holdings Limited 100% 100% 6. BlackRock, Inc.4242 143,210,2841,407,000 41
XV2 3 336 17 5. 242,439,857 9.57% 8 The Empire Trust* 0 20,000,000 0 20,000,000 ** 9.10 8.69 0 20,000,000 0 20,000,000 * The Empire Trust The Empire Trust ** 42
The Empire Trust 20,000,000 20,000,00020,000,0002,640,000 660,000 13.18 2,200,000,000 1,867.1 DSL 836,549,070 33.03% 13.18 43
34.65%890,094,000 3.85% 98,899,000 96.25% 41.69% 0.73% 44,326,000 (i)43.42%(ii) 1,085,230,0002,713,750,000 9.10 125,765,500 30%1,217,994,000 12.04% 97.78% 44
(i)43.42%(ii) 1,085,230,000 2,713,750,000 9.10125,765,500 30% 1,217,994,000 12.04% 10% 10% 14A 45
75,000,000 8% 52.1% 14A 42 42 46
6.1 47
48
5064 18317 1712 1716 25% 49
50
David Ross PARKINSON 3.10(1) 3.10(2) 3.10A 51
3.13 52
A B B B B B B David Ross PARKINSON B B B A B 53
A.2.1 54
4/4 2/2 4/4 2/2 4/4 2/2 4/4 2/2 4/4 2/2 4/4 2/2 4/4 2/2 David Ross PARKINSON 4/4 2/2 4/4 2/2 55
A.6.4 (a) (b) (c) (d) (e) 56
1. 2. 3. 57
3/3 3/3 3/3 1. 2. 3. 4. 5. 6. 58
1. 2. 3. 4. 5. 6. 7. 59
25 32 1,000,000 9 1,000,0011,500,000 5 1,500,0012,000,000 1 2,500,0013,000,000 1 3,000,000 2 65 60
61
4,958 1,997 1,990 98 87 9,130 3.29 15 62
www.hkexnews.hk www.3sbio.com 63
21 1 36ir@3sbio.com 64
Ernst & Young 22/F, CITIC Tower 1 Tim Mei Avenue Central, Hong Kong 1 22 Tel +852 2846 9888 Fax +852 2868 4432 ey.com 74 189 65
66
2,288,500,000 38 17 67
4,126,180,000 36 16 68
96.22% 36 69
70
71
72
Tong Ka Yan, Augustine 73
5 2,797,289 1,673,126 6 (402,268) (241,911) 2,395,021 1,431,215 5 215,594 208,618 (1,017,196) (585,585) (301,236) (301,044) 6 (282,223) (142,651) 7 (147,710) (26,545) 19 (12,182) 3,848 850,068 587,856 11 (135,814) (61,626) 714,254 526,230 712,564 526,280 1,690 (50) 714,254 526,230 13 0.28 0.23 13 0.28 0.23 74
714,254 526,230 19,858 (4,829) (21,504) 192,597 134,898 190,951 130,069 190,951 130,069 905,205 656,299 903,515 656,349 1,690 (50) 905,205 656,299 75
14 1,762,813 450,254 15 298,632 91,908 16 4,126,180 560,883 17 2,288,500 497,753 18 134 130 19 85,575 1,729,219 20 50,000 21 79,517 37,971 13,326 505,883 22 65,794 15,411 23 2,955 2,698 8,798,071 3,867,465 24 262,438 134,391 25 785,543 549,596 26 140,981 147,025 20 362,172 81,585 2,613 27 677,598 1,299,398 27 519,488 27 9,386 31,484 2,240,731 2,762,967 28 58,792 34,444 29 502,070 309,992 30 25,020 12,959 31 518,461 405,000 39,276 10,215 1,143,619 772,610 1,097,112 1,990,357 9,895,183 5,857,822 76
9,895,183 5,857,822 31 2,540,682 30 269,980 122,567 22 294,396 81,790 23,783 18,000 3,128,841 222,357 6,766,342 5,635,465 33 155 154 33 4,367,719 4,355,287 2,154,625 1,268,849 6,522,499 5,624,290 243,843 11,175 6,766,342 5,635,465 77
* * * * * 33 33 34 35 366,448 150,575 85,425 492,061 6,532 (168,674) 932,367 11,225 943,592 526,280 526,280 (50) 526,230 (4,829) (4,829) (4,829) 134,898 134,898 134,898 526,280 (4,829) 134,898 656,349 (50) 656,299 39,953 (39,953) 34 46,581 46,581 46,581 12 119 (119) 35 4,132,853 4,132,888 4,132,888 (143,895) (143,895) (143,895) 154 4,355,287 197,156 125,378 978,388 1,703 (33,776) 5,624,290 11,175 5,635,465 154 4,355,287 197,156 125,378 978,388 1,703 (33,776) 5,624,290 11,175 5,635,465 712,564 712,564 1,690 714,254 (1,646) (1,646) (1,646) 192,597 192,597 192,597 712,564 (1,646) 192,597 903,515 1,690 905,205 81,469 (81,469) 34 (5,307) (5,307) (5,307) 230,978 230,978 1 12,432 (12,432) 1 1 155 4,367,719 179,417 206,847 1,609,483 57 158,821 6,522,499 243,843 6,766,342 * 2,154,625,000 1,268,849,000 78
850,068 587,856 19 12,182 (3,848) 5,19 (102,818) 5 (6,117) 6 2,935 5,19 (66,871) (13,093) 5 (23,957) (33,525) 7 147,710 26,545 5,6 23,091 23,022 34 (5,307) 46,581 14 102,338 49,863 58,662 27,500 15 6,503 2,466 6 3,059 367 30 (35,247) (8,917) 25 (3,022) (437) 26 (869) 24 692 (1,730) 6 1,273 2,019 5 (21,811) 6 1,355 5 (2,192) 5 (21,504) 78,275 1,367 1,123,057 581,407 15,460 1,367 824 305 (125,715) (121,691) (48,221) (86,823) 324 11,152 3,029 150,011 144,258 1,126,568 520,809 (122,244) (65,535) 1,004,324 455,274 79
19,485 33,369 (116,439) (61,040) (806,752) (49,738) 574,093 70,000 (5,362) 21 (75,000) 27 (519,488) 27 519,488 5 2,192 (78,275) (30,000) (3,500) 3,500 36 (4,138,200) (835,014) 37 100,000 21,754 (1,385) (1,363,676) (505,883) (349,596) (36,483) 1,242 1,456 (4,381,009) (3,248,243) 4,132,888 (179,011) 24,448 222,769 3,985,116 752,362 300,000 (1,467,552) (1,034,791) (131,805) (25,919) 2,710,207 3,868,298 (666,478) 1,075,329 1,299,398 107,612 44,678 116,457 677,598 1,299,398 27 674,380 1,298,372 27 3,218 1,026 677,598 1,299,398 80
1. Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands * 1 100% * 2 100% * 100% 2,185,000,000 * 100% 15,000,000 81
1. * 100% 1,000,000 * 80% 250,000,000 * 1 100% Sirton Pharmaceuticals S.p.A.Sirton 300,000 100% * 10 100% 82
1. * 500,000 100% * 100% 160,000,000 * 100% 10,000,000 * 100% 56,500,000 * 8 100% 83
1. * 1 100% * 100% 29,100,000 * 96.25% 410,000,000 96.22% 510,223,050 61.54% 260,000,000 84
1. * 1,000,000 100% * 100% 150,000,000 * 100% 100,000,000 * 100% 1,034,100,000 * 85
1. 2.1 622 86
2.1 (a) (b) (c) (i) (ii) (iii) (i)(ii) (iii) 87
2.2 10 12 28 11 14 1 1638 1641 27 11638 (a) 1 (i) 1 (ii) (iii) (iv) 88
2.2 (b) 1638 1638 (c) 5 5 89
2.3 2 2 4 9 4 2 9 2 10 4 28 15 2 15 15 2 16 3 7 1 12 1 40 2 22 2 5 1 2 3 4 5 12 128 90
2.3 2 9 39 9 9 9 9 (a) 9 91
2.3 (b) 9 9 9 10281028 1028 92
2.3 1515 15 15 15 15 15 1617 4 15 27 40 1617 17 1616 93
2.3 7 12 94
2.4 20% 5 95
2.4 96
2.4 97
2.4 98
2.4 (a) (i) (ii) (iii) (b) (i) (ii) 99
2.4 (b) (iii) (iv) (v) (vi) (a) (vii) (a)(i) (viii) 100
2.4 10 45 5 12 2.5 12 4 10 101
2.4 5 25 14 25 5 20 1 10 102
2.4 103
2.4 30 50 104
2.4 (a) (b) 105
2.4 (a)(b) 106
2.4 107
2.4 108
2.4 39 39 109
2.4 (i) (ii) 110
2.4 (i) (ii) 111
2.4 112
2.4 113
2.4 (a) (b) (c) (d) 114
2.4 34 115
2.4 116
2.4 117
2.4 118
2.4 3. 119
3. 4,126,180,000 560,883,000 16 22 120
3. 121
3. 34 20 122
4. (a) 2,684,323 1,582,588 112,966 90,538 2,797,289 1,673,126 (b) 6,543,900 3,637,066 2,058,260 214,388 8,602,160 3,851,454 269,177,000 172,907,000 9.6%10.3% 123
5. 2,810,622 1,683,018 (13,333) (9,892) 2,797,289 1,673,126 (a) 18,897 6,046 (b) 53,052 9,889 23,957 33,525 13,285 3,114 11,491 6,233 670 2,192 3,486 6,161 121,102 70,896 66,871 13,093 21,504 6,117 102,818 21,811 94,492 137,722 215,594 208,618 124
5. (a) 30 (b) 6. 402,268 241,911 14 102,338 49,863 58,662 27,500 15 6,503 2,466 3,059 367 9,586 6,744 9,130 7,211 8 439,712 236,986 (5,307) 46,581 40,017 15,082 53,831 28,701 528,253 327,350 243,006 111,324 19 1,355 1,273 2,019 25 (3,022) (437) 26 (869) 23,091 23,022 2,935 14,454 6,723 282,223 142,651 125
7. 147,710 26,545 8. 383(1)(a) (b) (c) (f)2 7,645 3,232 2,098 1,865 582 557 10,325 5,654 126
8. (a) David Ross Parkinson 257 257 257 257 257 257 771 771 David Ross Parkinson* 140 140 * 140 140 * 140 140 420 420 * 127
8. (b) 2,424 518 169 3,111 498 668 82 1,248 664 480 82 1,226 * 3,288 432 249 3,969 6,874 2,098 582 9,554 128
8. (b) 897 460 159 1,516 649 476 82 1,207 487 497 82 1,066 * 779 432 234 1,445 2,812 1,865 557 5,234 * 129
9. 8 6,251 1,744 240 83 6,491 1,827 1,000,000 1,000,001 1,500,000 1,500,001 2,000,000 1 2,000,001 2,500,000 1 2,500,001 3,000,000 1 3,000,001 3,500,000 1 3 1 10. 20% 30% 40,599,000 15,639,000 130
11. 25% 15% Sirton31.4% 10% 145,674 69,480 22 (9,860) (7,854) 135,814 61,626 131
11. 850,068 587,856 25% 212,517 146,964 (92,611) (42,060) (28,446) (12,446) (31,473) (43,504) 57,746 20,521 (3,676) (29) (6,144) 18,100 1,284 10 687 135,814 61,626 16.0%10.5% 12. 119 19,000 Decade Sunshine LimitedDecade Sunshine 132
13. 2,524,049,681 2,255,271,762 712,564 526,280 2,524,049,681 2,255,271,762 39,440,661 43,462,623 2,563,490,342 2,298,734,385 133
14. 342,678 222,327 65,344 8,333 33,290 671,972 (85,902) (89,517) (40,259) (6,040) (221,718) 256,776 132,810 25,085 2,293 33,290 450,254 256,776 132,810 25,085 2,293 33,290 450,254 230 11,016 16,102 1,781 90,792 119,921 36 376,998 256,842 11,945 1,849 648,721 1,296,355 (245) (1,958) (306) (6) (2,515) (36,261) (53,291) (11,361) (1,425) (102,338) 3,913 2,033 (5,946) 555 557 14 4 6 1,136 598,053 349,889 43,512 4,496 766,863 1,762,813 790,386 674,686 105,203 14,761 766,863 2,351,899 (192,333) (324,797) (61,691) (10,265) (589,086) 598,053 349,889 43,512 4,496 766,863 1,762,813 3,721,000 3,613,000 8,738,000 8,679,000 39,552,000 49,538,000 31 134
14. 251,453 200,831 56,053 6,831 12,849 528,017 (49,498) (68,023) (32,116) (4,390) (154,027) 201,955 132,808 23,937 2,441 12,849 373,990 201,955 132,808 23,937 2,441 12,849 373,990 1,378 10,381 5,338 106 26,417 43,620 36 112,800 19,314 3,388 803 1,508 137,813 (1,224) (1,914) (201) (136) (3,475) 37 (39,787) (4,927) (986) (147) (3,968) (49,815) (17,358) (25,085) (6,649) (771) (49,863) 3,237 279 (3,516) (988) (1,004) (21) (3) (2,016) 256,776 132,810 25,085 2,293 33,290 450,254 342,678 222,327 65,344 8,333 33,290 671,972 (85,902) (89,517) (40,259) (6,040) (221,718) 256,776 132,810 25,085 2,293 33,290 450,254 135
15. 94,382 88,670 37 (10,022) 36 218,600 18,200 (6,503) (2,466) 306,479 94,382 26 (7,847) (2,474) 298,632 91,908 3050 6,442,000 6,775,000 31 16. 230,597 36 330,286 560,883 560,883 36 3,327,399 237,898 4,126,180 4,126,180 4,126,180 136
16. 16.0% 3% 137
17. 39,510 384,144 35,229 38,870 497,753 335,490 12,791 1,316 349,597 36 1,430,641 69,775 17,300 1,517,716 (3,321) (53,405) (21,227) (9,813) (87,766) 11,213 (13) 11,200 343,382 1,416,746 362,917 117,795 47,660 2,288,500 352,203 1,714,403 422,897 117,795 65,178 2,672,476 (8,821) (297,657) (59,980) (17,518) (383,976) 343,382 1,416,746 362,917 117,795 47,660 2,288,500 138
17. 4,317 336,884 35,229 29,115 405,545 36,483 36,483 36 66,100 17,152 83,252 37 (13) (13) (1,290) (18,840) (7,370) (27,500) (14) (14) 39,510 384,144 35,229 38,870 497,753 5,500 42,312 422,897 35,229 46,444 552,382 (5,500) (2,802) (38,753) (7,574) (54,629) 39,510 384,144 35,229 38,870 497,753 2.4 26.0% 18.0% 19.0% 139
17. 18. 130 130 130 103 27 4 134 130 Injenerics Srl ( Injenerics ) 10,000 50 50 50 140
18. 134 130 19. 86,930 938,118 791,101 86,930 1,729,219 (1,355) 85,575 1,729,219 141
19. % % (a)(b) 2,142 27.04 (a)(c) 10,873,796 14.5 (a)(d) 5,000,000 40 (a) (b) 5,285,000 6,857,000 1,283,000 2,160 32.4%27.04% (c) 27.041% 1,676,000 18.86% 14.5% (d) 142
19. (12,182) 3,848 (12,182) 3,848 85,575 1,729,219 143
20. (i) 361,517 70,690 (ii) 655 10,895 362,172 81,585 (iii) 50,000 (i) (ii) (iii) 23.81% 50,000,000 144
21. 81,362 1,845 (1,845) (1,845) 79,517 52.1% 75,000,000 8% 4,517,000 1,845,0003 5 1,845 2,119 (274) 1,845 1,845 145
22. 8,500 310 871 626 1,244 11,551 11 1,366 (259) (899) (148) 935 995 36 212 1,641 1,012 2,865 9,866 263 (28) 2,119 3,191 15,411 9,866 263 (28) 2,119 3,191 15,411 11 3,885 33 527 (104) (4,743) (402) 36 14,083 301 36,349 50,733 52 52 27,834 296 499 2,316 34,849 65,794 146
22. (a) 77,697 5,412 (b) 65,013 55,011 2,916 142,710 63,339 (a) (b) 147
22. 69,945 3,676 73,621 11 (3,183) (3,676) (6,859) 36 15,028 15,028 81,790 81,790 81,790 81,790 11 (10,262) (10,262) 36 222,868 222,868 294,396 294,396 10% 5% 10% 148
22. 2,136,319,000 985,640,000 23. 600 600 2,355 2,098 2,955 2,698 24. 50,479 20,859 160,001 77,880 43,199 26,664 10,434 9,971 264,113 135,374 (1,675) (983) 262,438 134,391 692,000 1,730,000 149
25. 688,396 425,922 108,767 138,305 797,163 564,227 (11,620) (14,631) 785,543 549,596 286,241 200,802 356,288 188,335 20,392 12,127 13,855 9,992 4,547 12,483 7,073 2,183 688,396 425,922 150
25. 14,631 4,722 653 3,332 (3,675) (3,769) 10,939 (645) 11 52 11,620 14,631 642,529 389,137 20,392 12,127 13,855 10,027 676,776 411,291 151
26. 114 159 14,456 9,110 7,847 2,474 54,468 19,654 26,651 42(b) 38,586 115,628 142,122 147,025 (1,141) 140,981 147,025 5,692 (1,141) 2,010 (2,010) (5,692) (1,141) 152
27. 674,380 1,298,372 3,218 1,026 9,386 550,972 686,984 1,850,370 (3,499) (1,149) 31 (5,887) (30,335) (519,488) 677,598 1,299,398 276,303 716,420 38,567 241,522 362,863 882,297 9,249 10,128 2 3 686,984 1,850,370 9,386,000 31,484,000 31 153
28. 44,154 23,262 6,833 3,442 7,805 7,740 58,792 34,444 29. 144,056 78,694 141,177 51,523 42(b) 118,946 113,324 31,245 19,608 18,420 2,515 6,330 15,557 3,927 6,084 2,709 1,709 7,082 35,260 13,896 502,070 309,992 154
30. 135,526 18,734 (a) 26,053 36 170,878 134,847 37 (9,138) (2,210) (a) (35,247) (8,247) (b) (670) 295,000 135,526 (25,020) (12,959) 269,980 122,567 (a) (b) DaVita China Pte. LtdDaVita China4,822,700 155
31. 518,461 405,000 2,540,682 3,059,143 405,000 1,192,000 405,000 1,867,143 3,059,143 405,000 518,461 405,000 845,709 1,694,973 3,059,143 405,000 (a) 2.5% 6.72% (i) 45,994,000 56,313,000 (ii) 5,887,000 30,335,000 (iii) 30,940,000 32,854,000 (iv) 31.76%100% Full Gain 43.42% (b) 2.50% (c) 156
32. TFR TFR TFR TFR TFR19 TFR 157
32. % 1.2 1.7 % 2.2 3.0 % % 0.5 231 0.5 251 0.5 242 0.5 261 158
32. 103 69 103 69 103 69 5,727 6,600 103 69 (457) (473) 127 (135) 172 (334) 5,672 5,727 15 15 159
33. 2,532,313,570 2,515,313,570 155 154 0.00001 2,515,313,570 154 4,355,287 4,355,441 17,000,000 1 12,432 12,433 0.00001 2,532,313,570 155 4,367,719 4,367,874 34. 6.96% 1,128.82033 1.00 1.00 0.00001112,882,033 1.00 0.00001 160
34. % % 37.50 % 1.10 3.50 70.50 0.00006 30% 50%19.37 32.26 5,307,000 46,581,000 39,441,017 39,441,0173,000 112,882,033 11,288,20345,152,812 17,000,0000.0000117,000,000 1,00012,432,000 33 7.77 161
34. TMF (Cayman) Ltd.TMFThe Empire Trust The Empire Trust 20,000,000 9.10 TMF 20,000,000 20,000,000 20,000,000 TMF7.30 20,000,0001.0% 35. 1 10%50% 162
36. 28.8% 96.22% 890,094,00098,899,000 34.65% 3.85%96.25% 41.69% 0.73% 44,326,000 30% 1,217,994,000 163
36. (i)43.42%(ii) 1,085,230,0003,229,501,0002,713,750,000 9.1125,765,500 164
36. 1,296,355 218,600 1,517,716 50,733 28,398 114,938 106,925 313,885 77,735 320,981 3,174 (12,994) (55,606) (8,900) (5,551) (170,878) (222,868) 3,572,643 (230,978) 3,327,399 6,669,064 4,459,181 505,883 28.8% 1,704,000 6,669,064 165
36. 4,459,181 (320,981) 4,138,200 797,101,000270,064,000 2,936,312,000 687,592,000 166
36. 100% 520,000,000 8,000,000 137,813 18,200 83,252 928 2,865 34,127 80,226 11,953 30,000 62,167 (6,144) (36,892) (70,000) (906) (134,847) (15,028) 197,714 16 330,286 520,000 8,000 528,000 167
36. 520,000 (62,167) 457,833 103,267,00015,075,000 1,812,731,000 507,200,000 168
37. 100% 100,000,000 100,000,000 49,815 10,022 13 10,471 25 17,195 270 1,589 328 1,749 (9,138) (4,150) (100,000) (21,811) 21,811 169
37. (10,471) (10,471) 38. 39. 31 170
40. 4,685 1,717 3,533 5,055 8,218 6,772 41. 40 110,130 24,182 69,370 800 3,200 180,300 27,382 171
42. Century Sunshine LimitedCentury Sunshine Decade Sunshine Injenerics DaVita 172
42. (a) (i) 1,761 4,500 21 79,517 (ii) 30,000 3,500 1,000 (iii) 100,000 (iv) 300,128 (v) 5,000 (i) 761,000 4,000,000 1,000,000 500,000 (ii) 200,000,00010,000,000 3.85% (iii) 100,000,000 37 (iv) 300,000,0003.85% (v) 5,000,000 173
42. (b) 30,000 104,500 Injenerics 475 805 7,921 10,323 DaVita 190 38,586 115,628 79,517 9,341 10,726 Century Sunshine 109,605 102,598 118,946 113,324 (c) 8 9 174
43. 79,517 79,517 50,000 50,000 600 600 785,543 785,543 63,428 63,428 362,172 362,172 2,613 2,613 677,598 677,598 9,386 9,386 1,616,072 414,785 2,030,857 58,792 179,262 18,111 3,059,143 3,315,308 175
43. 600 600 549,596 549,596 135,441 135,441 81,585 81,585 1,299,398 1,299,398 519,488 519,488 31,484 31,484 2,536,007 81,585 2,617,592 34,444 141,546 12,273 405,000 593,263 176
44. 67,765,000 38,583,000 177
45. 412,172 81,585 412,172 2,613 2,613 79,517 79,517 494,302 81,585 494,302 2,540,682 2,540,682 5,000 4,729 2,545,682 2,545,411 178
45. 10% 10% 70,000 179
45. 655 655 50,000 50,000 361,517 361,517 2,613 2,613 655 364,130 50,000 414,785 10,895 10,895 70,690 70,690 10,895 70,690 81,585 180
45. 79,517 79,517 2,540,682 2,540,682 4,729 4,729 2,545,411 2,545,411 181
46. 31 27 182
46. 25 183
46. 44,154 14,638 58,792 23,176 156,086 179,262 18,111 18,111 35,000 483,461 2,540,682 3,059,143 102,330 654,185 2,558,793 3,315,308 23,262 8,323 2,859 34,444 39,156 18,952 83,438 141,546 12,273 12,273 400,000 5,000 405,000 462,418 32,275 98,570 593,263 184
46. 15,288 15,422/11,843 13,010 15,451/12,696 762 839/474 526 707/496 185
46. 10% 10,014 1,001/(1,001) 186
46. 3,059,143 405,000 6,766,342 5,635,465 45.2% 7.2% 187
47. 1,619 1,619 2,973,736 92,183 76,934 67,783 3,052,289 161,585 10,014 13,896 2 1,681,351 4,165,490 110,501 189,591 1,805,748 4,365,097 10,961 11,396 10,961 11,396 1,794,787 4,353,701 4,847,076 4,515,286 13,111 12,273 13,111 12,273 4,833,965 4,503,013 155 154 4,296,431 4,283,999 537,379 218,860 4,833,965 4,503,013 188
47. 295,160 6,532 (220,265) 191,549 272,976 (5,129) 255,344 (9,171) 241,044 (119) (119) 34 46,581 (46,581) 4,132,853 4,132,853 (143,895) (143,895) 4,283,999 46,581 1,403 35,079 135,797 4,502,859 (1,403) 310,006 27,655 336,258 34 (5,307) (5,307) 12,432 (12,432) 4,296,431 28,842 345,085 163,452 4,833,810 48. 189
1. 1.1 ESG 190
1.2 SFE 191
EHS ESG ESG ESG ESG 192
ESG 2. 2.1 Good Manufacturing Practice GMP 193
2.2 LED 194
0.6KWh 0.03KWh 1.14KWh 0.091KWh LED LED 50% 10 12156%53 77424968% 195
83,824 26,075 0.0061 0.0016 6,358,107 3,745,990 0.46 0.23 115,189 0.0072 20,956 14,895 0.0015 0.0010 707,250 416,221 0.0500 0.0260 175.94 240.00 0.000013 0.000015 2.3 196
KT PS 5.6 197
219.35 0.000014 2.21 14.9 2.21 0 0.00000016 0 0.72 40.1 0.00000005 0.0000025 3. 2,000 5,900 198
3.1 GMP (CFDA) GMP GMP Amgen 1 1 Amgen (2008) Biochemical Assessment of Erythropoietin Products From Asia Versus US Epoetin alfa Manufactured by Amgen, available from www.interscience,wiley.com 199
30 17 48631 1 215 60 200
50100 3.2 201
100% 24 202
GMP cgmp SFESales Force Effectiveness 203
4. GMP 4.1 GMP 204
(SOP)I II III IV I II III IV I II III 4.2 I II 1GMPI 205
849 178 84 117 248 91 34 44 4 49 832 17 % 100 206
5. 5.1 207
3,465 1,646 1,662 3,290 18 >50 74 30 50 2,280 <30 954 3,302 6 % 14 % 17 % 12 >50 % 21 30 50 % 12 <30 % 18 % 14 % 33 1 Sirton Sirton 2 = + 100% 208
209
210
% 100 385.85 43.18 1,222 5.2 211
5,934 0 0 0 % 100 212
5.3 1,442 213
5.4 214
1,106 1,217 26.79 7.04 % 100 100 % 100 100 % 100 100 % 100 100 % 100 100 % 100 100 73.00 3.55 6. 6.1 215
216 (ITP) 6 8,000 12,000 2,000 170 300 + 6 5,000 15,000
12 3 3,229 36.5% 60.74% + 1,000 10% + + 65,00015,000 217
6.2 7,301 47,219 2015 4 17 ITP 2015 10 16 2015 11 12 218
29030,000 50%60% 13,380 24%50% 80% 18 820 219
TCP ThrombocytopeniaTCP TCPTCP 2015 8 TCP TCP Thrombocytopenia TCPTCPTCP 45 6.3 GMP 220
WHO CFDA 221
6.4 2016 2016 2015 2015 2014 2014 222
2014 2014 2016 2015 223
7. ESG ESG (IPE) 224